ArticleBMC surgery2026
Unilateral Endo-LIF in treating central lumbar spinal stenosis.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeTo investigate the clinical efficacy and morphological alterations in the central canal following unilateral-approach endoscopic lumbar interbody fusion (Endo-LIF) for treating central lumbar spinal stenosis (CLSS) with neurogenic claudication.
methodsFrom January 2021 to January 2023, 33 patients with CLSS who received unilateral Endo-LIF were retrospectively analyzed. A qualitative analysis of dural sac morphology was performed utilizing MRI scans. The dural sac cross-sectional area (DSCA), contralateral ligamentum flavum thickness (LFT) and contralateral foramen height (FH) were quantitatively measured. The clinical outcomes were assessed using the Visual Analog Scale (VAS), Oswestry Disability Index (ODI), and modified MacNab criteria.
resultsThis study enrolled 33 patients with a mean follow-up period of 22.57 months. Qualitative central canal parameters significantly improved after unilateral-approach Endo-LIF (p < 0.001). Compared with preoperative value, significant increases in DSCA (90.7 ± 30.7%) and contralateral FH (19.7 ± 5.0%), and significant decreases in contralateral LFT (20 ± 4.0%) were found (p < 0.001). Postoperative VAS and ODI scores showed statistically significant decreases at all follow-up intervals (1, 3, and 12 months) and at final assessment (p < 0.05). The patients were rated as excellent in 19 cases and good in 12 cases (93.9%) based on the modified MacNab standard.
conclusionUnilateral-approach Endo-LIF can significantly improve the area of the central canal. Therefore, Endo-ILF unilateral direct decompression may be a promising option for CLSS with bilateral symptoms. (one side is mild).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.